Slate Medicines will merge with Fulcrum Therapeutics in a reverse-merger structure as the companies reposition for migraine drug development. The transaction follows Fulcrum’s discontinuation of its sickle cell program after regulatory concerns, and sets up a combined portfolio approach for headache assets. Alongside the merger, Slate secured $245 million in financing to support Phase 1 testing of its lead migraine candidate and additional pipeline programs. The deal structure assigns Fulcrum pre-merger shareholders a minority equity stake, while Slate’s investors retain control. For the sector, the headlines reinforce that reverse mergers remain a funding and listing route for biotechs with early clinical or platform-driven differentiation—especially when traditional exits are constrained.